MX2017000142A - Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. - Google Patents

Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.

Info

Publication number
MX2017000142A
MX2017000142A MX2017000142A MX2017000142A MX2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A
Authority
MX
Mexico
Prior art keywords
stromal cells
mesenchymal stromal
treating sepsis
sepsis
treating
Prior art date
Application number
MX2017000142A
Other languages
English (en)
Inventor
Dekker Robert
Lombardo Eleuterio
Dalemans Wilfried
Original Assignee
Tigenix S A U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A U filed Critical Tigenix S A U
Publication of MX2017000142A publication Critical patent/MX2017000142A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)

Abstract

La invencion se refiere al uso de celulas estromales mesenquimatosas (MSCs) para tratar la sepsis en un sujeto. La invencion proporciona composiciones, usos y metodos para el tratamiento de la sepsis.
MX2017000142A 2014-06-30 2015-06-30 Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. MX2017000142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14175095 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (1)

Publication Number Publication Date
MX2017000142A true MX2017000142A (es) 2017-07-28

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000142A MX2017000142A (es) 2014-06-30 2015-06-30 Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.

Country Status (14)

Country Link
US (2) US20170151284A1 (es)
EP (1) EP3160481B1 (es)
JP (1) JP6722599B2 (es)
KR (1) KR102213527B1 (es)
CN (1) CN106573017B (es)
AU (1) AU2015283662B2 (es)
BR (1) BR112016030758B8 (es)
CA (1) CA2953884C (es)
IL (1) IL249814B (es)
MX (1) MX2017000142A (es)
NZ (1) NZ727950A (es)
RU (1) RU2715866C2 (es)
SG (1) SG11201610844PA (es)
WO (1) WO2016001846A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11518982B2 (en) * 2015-12-01 2022-12-06 Adiposeeds, Inc. Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue
US11701389B2 (en) 2016-03-09 2023-07-18 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
EP3589298B1 (fr) 2017-02-28 2022-06-22 Université de Lorraine Cellules souches mesenchymateuses issues de la gelée de wharton pour le traitement du sepsis
EP3700524A4 (en) 2017-10-26 2021-08-25 Emory University MCL-1 INHIBITORS, COMPOSITIONS AND USES IN THE MANAGEMENT OF CANCER
SG11202011927TA (en) * 2018-06-05 2020-12-30 Medipost Co Ltd Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
KR20210086662A (ko) * 2018-10-29 2021-07-08 오타와 하스피털 리서치 인스티튜트 Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도
US20230086254A1 (en) * 2020-01-30 2023-03-23 Jcr Pharmaceuticals Co., Ltd. Medicinal composition comprising dental pulp-derived cells
CN117835994A (zh) * 2021-05-13 2024-04-05 普干基因美国有限公司 用于治疗肝病的方法和组合物
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627175A (en) 1992-12-02 1997-05-06 Shellinternationale Research Maatschappij B.V. Azoxycyanobenzene compounds
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
EP0832271B8 (en) 1995-06-07 2005-03-02 INEX Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP2824174B1 (en) * 2004-03-22 2018-11-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
ES2751692T3 (es) 2005-09-23 2020-04-01 Tigenix S A U Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
WO2012125471A1 (en) * 2011-03-11 2012-09-20 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
RU2715866C2 (ru) 2020-03-03
EP3160481B1 (en) 2020-09-09
EP3160481A1 (en) 2017-05-03
WO2016001846A1 (en) 2016-01-07
AU2015283662A1 (en) 2017-01-19
KR20170021343A (ko) 2017-02-27
RU2016151738A3 (es) 2019-01-30
CN106573017A (zh) 2017-04-19
BR112016030758A2 (es) 2017-08-22
US20170151284A1 (en) 2017-06-01
BR112016030758B8 (pt) 2022-10-25
SG11201610844PA (en) 2017-01-27
CA2953884A1 (en) 2016-01-07
JP2017520583A (ja) 2017-07-27
CA2953884C (en) 2022-12-06
IL249814B (en) 2020-02-27
US20200376038A1 (en) 2020-12-03
RU2016151738A (ru) 2018-07-30
CN106573017B (zh) 2021-06-11
NZ727950A (en) 2022-07-01
KR102213527B1 (ko) 2021-02-09
IL249814A0 (en) 2017-03-30
BR112016030758B1 (pt) 2021-10-13
AU2015283662B2 (en) 2020-09-24
JP6722599B2 (ja) 2020-07-15

Similar Documents

Publication Publication Date Title
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
PH12016501763A1 (en) Multispecific antibodies
IL251576A0 (en) Methods and compositions for creating or maintaining multifunctional cells
MX2015012334A (es) Metodos y composiciones para el control de malezas.
MX370807B (es) Anticuerpos que se unen a axl.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2017010150A (es) Bacterias probioticas recombinantes.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
PH12017500836A1 (en) Transdermal formulations
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
NZ730014A (en) Compound targeting il-23a and tnf-alpha and uses thereof
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2017000306A (es) Metodos para tratar hipotension.
IL251616B (en) Methods and compounds for the treatment and prevention of muscle mass loss
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
IN2014MU00455A (es)
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
HK1254588A1 (zh) 間充質幹細胞用於治療骨關節炎的用途
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
IN2014CH00151A (es)
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.